A Bayesian method for synthesizing multiple diagnostic outcomes of COVID-19 tests

Lirong Cao1,4,†, Shi Zhao1,4,†, Qi Li1,4,†, Lowell Ling2, William K. K. Wu2, Lin Zhang2, Jingzhi Lou1, Marc K. C. Chong1,4, Zigui Chen3, Eliza L. Y. Wong1, Benny C. Y. Zee1,4, Matthew T. V. Chan2, Paul K. S. Chan3 and Maggie H. Wang1,4

1JC School of Public Health and Primary Care, 2Department of Anaesthesia and Intensive Care, 3Department of Microbiology, Stanley Ho Centre for Emerging Infectious Diseases, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, People’s Republic of China
4Clinical Trials and Biostatistics Lab, CUHK Shenzhen Research Institute, Shenzhen, People’s Republic of China

The novel coronavirus disease 2019 (COVID-19) has spread worldwide and threatened human life. Diagnosis is crucial to contain the spread of SARS-CoV-2 infections and save lives. Diagnostic tests for COVID-19 have varying sensitivity and specificity, and the false-negative results would have substantial consequences to patient treatment and pandemic control. To detect all suspected infections, multiple testing is widely used. However, it may be challenging to build an assertion when the testing results are inconsistent. Considering the situation where there is more than one diagnostic outcome for each subject, we proposed a Bayesian probabilistic framework based on the sensitivity and specificity of each diagnostic method to synthesize a posterior probability of being infected by SARS-CoV-2. We demonstrated that the synthesized posterior outcome outperformed each individual testing outcome. A user-friendly web application was developed to implement our analytic framework with free access via http://www2.ccrb.cuhk.edu.hk/statgene/COVID_19/. The web application enables the real-time display of the integrated outcome incorporating two or more tests and calculated based on Bayesian posterior probability. A simulation-based assessment demonstrated higher accuracy and precision of the Bayesian probabilistic model compared with a...
single-test outcome. The online tool developed in this study can assist physicians in making clinical evaluations by effectively integrating multiple COVID-19 tests.

1. Background

The ongoing coronavirus disease 2019 (COVID-19) pandemic is causing substantial morbidity and mortality globally [1]. Diagnosis is of importance to control outbreaks, especially in the absence of specific treatments or vaccines. To date, COVID-19 is commonly diagnosed by the detection of unique sequences of SARS-CoV-2 RNA using the nucleic acid amplification tests (NAAT), e.g. real-time reverse transcription–polymerase chain reaction (RT-PCR) [2]. However, suboptimal sample collection, storage and transportation may lead to false-negative results. The sensitivity of laboratory-based molecular testing is largely dependent on the types of specimens and the time of collection from the onset of illness [3], which also leads to an extensive range of sensitivity for RT-PCR in previous studies, between 46% and 92% [4–8].

As the RT-PCR test might fall short of testing capacity and timeliness in some regions, recent studies proposed that chest computed tomography (CT) scans could be included as a supplementary diagnostic tool if there are clinical symptoms, epidemiological characteristics and imaging characteristics of viral pneumonia that are compatible with COVID-19 infection in epidemic areas [8]. Although using chest CT may be helpful, the specificity is low due to the absence of pathognomonic CT features, which is even lower than 50% according to earlier research findings [9]. In addition, serological tests are also recommended as a supplement for nucleic acid detection, because the antibody-based methods are relatively cheap, easy to operate and have lower technical requirements [10]. Since the detection of antibodies against SARS-CoV-2 is more accurate in the middle to later stages of COVID-19, antibody tests are primarily used to determine whether a person has been previously infected. In many prior reports, the sensitivity for combined IgM and IgG detection is higher than 71% and the specificity is higher than 90% [11–16].

None of the commonly used diagnostic tests, e.g. RT-PCR, chest CT and serological tests, alone is sufficiently accurate to provide absolute diagnostic certainty [10,17]. In view of the advantages and shortages of each detection method, parallel or serial tests are recommended in the clinic and the results are cross-referenced to improve diagnostic yield [18]. However, clinicians will face immense difficulty diagnosing COVID-19 when the test results are inconsistent. In this study, we provided a Bayesian method to synthesize multiple diagnostic outcomes and developed an online tool to evaluate the probability of an individual being infected by SARS-CoV-2.

2. Methods

2.1. Bayesian probabilistic framework

With the knowledge of the sensitivity and specificity of each COVID-19 diagnostic test, we constructed a Bayesian probabilistic model to synthesize multiple testing outcomes for an individual subject. We calculated the posterior probability of having COVID-19 based on the information and the outcomes of more than one test. Although the outcomes of different tests may be correlated, they are assumed conditionally independent with the disease status fixed when these tests are based on the different biological attributes [19]. Thus, the Bayesian probabilistic framework is applicable to infer the probability of disease status with correlated testing outcomes [20–22].

We considered that one individual subject receives M diagnostic tests, where M is an integer and $M > 1$. The testing outcome, i.e. positive or negative, is denoted by $T_i$ for the ith test. We defined $T_i$ as a binary outcome that is 1 for positive testing outcome and 0 otherwise. We denoted the event that ‘the individual subject has COVID-19’ by $D$ (stands for ‘diagnosed’ or ‘diseased’). For convenience, we also denoted the complement of event $D$, i.e. ‘the individual subject does not have COVID-19’, by $N$ (stands for ‘not diagnosed’). Straightforwardly, the summation of the probabilities (Pr) of $D$ and $N$ was 1.

The posterior probability of $D$ conditional on the $M$ testing outcomes is $\text{Pr}(D | T_1, T_2, \ldots, T_M)$. Hence, by using the Bayes theorem, the $\text{Pr}(D | T_1, T_2, \ldots, T_M)$ can be computed by using equation (2.1). Based on the intuition of the Bayes framework, the test with higher sensitivity or specificity will be automatically...
assigned with a higher weight,

\[
\Pr(D|T_1, T_2, \ldots, T_M) = \frac{\Pr(T_1, T_2, \ldots, T_M|D) \cdot \Pr(D)}{\Pr(T_1, T_2, \ldots, T_M)} = \frac{\Pr(T_1, T_2, \ldots, T_M|D) \cdot \Pr(D) + \Pr(T_1, T_2, \ldots, T_M|N) \cdot \Pr(N)}{\Pr(D) \cdot \Pr(T_1|D) + \Pr(N) \cdot \Pr(T_1|N)}.
\]

Here, \(\Pr(T_i = 1|D)\) is the sensitivity of the \(i\)th test, and \(\Pr(T_i = 0|D)\) is its \((1 - \text{sensitivity})\). The \(\Pr(T_i = 0|N)\) is the specificity of the \(i\)th test, and \(\Pr(T_i = 1|N)\) is its \((1 - \text{specificity})\). The \(\Pr(D)\) indicated the pre-test probability of having COVID-19 for an individual who receives tests. An alternative interpretation of \(\Pr(D)\) is the prevalence of COVID-19 among the testing subjects if there is no contact history or symptom. The prevalence among testing populations is available for each region in the ‘Our World in Data’ website [23]. The testing performance of each COVID-19 diagnostic test can be summarized from existing literature or obtained from the clinical evaluations of commercial testing kits. Hence, \(\Pr(D|T_1, T_2, \ldots, T_M)\) is computable. Additionally, if the testing subjects are at higher exposure risk, like healthcare practitioners or customs officers, the pre-test probability should be adjusted to a higher range and vice versa.

### 2.2. COVID-19 diagnostic assessment tool

The theoretical framework can be conducted to integrate multiple diagnostic test results for COVID-19. To facilitate public use, we set up an open-access and user-friendly online application of our framework. The application is available at [http://www2.ccrb.cuhk.edu.hk/statgene/COVID_19/](http://www2.ccrb.cuhk.edu.hk/statgene/COVID_19/). The user interface was designed to be intuitive, see figure 1. The ‘setup testing information and outcomes’ section offers users an option to indicate conducted tests, sensitivity and specificity, and testing outcome (positive or negative). Test 1, Test 2 and Test 3 can be diagnostic tests such as RT-PCR, chest CT and antibody test, or they can be repeated measures of a same test. After inputting the pre-test probability of an individual with suspected exposure, the ‘results’ section will show the posterior probability of the subject being infected with COVID-19 according to the above settings. A detailed user manual is also available in the web application. Many factors, such as variation of the incubation period, the severity of disease and sample quality, might impact the sensitivity and specificity of diagnostic tests [24]. Users are suggested to adjust these parameters accordingly.
2.3. Performance evaluation for the Bayesian method

We further simulated disease diagnosis according to the posterior probability. The $\Pr(D|T_1, T_2, \ldots, T_M) > 0.5$ was considered as positive cases for COVID-19. The tested population set in the simulation modelling was set as one million. The performance of the combined method by integrating multiple testing outcomes was compared with that of a single test by accuracy and precision. The accuracy and precision can be, respectively, computed in equations (2.2) and (2.3).

\[
\text{Accuracy} = \frac{(TP + TN)}{(TP + TN + FP + FN)} \tag{2.2}
\]

and

\[
\text{Precision} = \frac{TP}{(TP + FP)}. \tag{2.3}
\]

Here, TP is the number of true positive subjects, FP is the number of false-positive subjects, TN is the number of true negative subjects and FN is the number of false-negative subjects. All analysis was conducted in R statistical software (v. 3.5.1) [25].

3. Results

In figure 2, we demonstrated the relationship between the probability of having COVID-19 and the prevalence of COVID-19 among testing subjects under a two-test scenario as an example. The sensitivities were assumed to be at 95% and 80%, and the specificities were assumed to be at 80% and 50%, for test #1 and test #2, respectively. Four combinations of the testing outcomes were considered including ($T_1 = \text{positive}$, $T_2 = \text{positive}$) in figure 2a, ($T_1 = \text{positive}$, $T_2 = \text{negative}$) in figure 2b, ($T_1 = \text{negative}$, $T_2 = \text{positive}$) in figure 2c, and ($T_1 = \text{negative}$, $T_2 = \text{negative}$) in figure 2d. The online tool is also available for three diagnostic tests synthetization and serial testing synthetization (http://www2.ccrb.cuhk.edu.hk/statgene/COVID_19/).
For comparison purposes, we reported the performance of a single test and the Bayesian probabilistic
model for multiple tests in COVID-19 diagnosis, given a pre-test probability from 0.001% to 25%,
sensitivities and specificities for both $T_1$ and $T_2$ from 55% to 100% in figure 3. $T_1$ and $T_2$ could be
two types of tests, or repeated tests for different samples. The mean accuracy for the Bayesian probabilistic
model is 88%, which is higher than 81% for $T_1$ and 74% for $T_2$. The mean precision is also largest for
the Bayesian probabilistic model (51%) compared with $T_1$ (43%) and $T_2$ (36%) alone. We also
performed another simulation by setting a lower pre-test probability (0.001–5%), see electronic
supplementary material, figure S1. The results are consistent, and both show that the performance of
the Bayesian model is much better than individual tests.

4. Discussion

Rapid and accurate diagnosis of SARS-CoV-2 infections could facilitate timely control of the outbreaks of
COVID-19 by early detection. The characteristics of three detection methods, RT-PCR, chest CT and
serological tests, against COVID-19 are distinct, which may cause large variation in accuracy when
these tests are applied to different courses of the illness or patients with non-identical symptoms [26].
The testing performance for RT-PCR against different types of specimens varies according to the
previous studies. Outcomes obtained from samples of the lower respiratory tract, like sputum
specimens, are more accurate than that of the upper tract, e.g. nasal swabs and throat swabs, in
COVID-19 diagnosis [27,28]. Since the exact time of onset is sometimes unknown, particularly for
mild patients, and not all patients with COVID-19 could produce sputum for diagnostic evaluation,
parallel or serial testing is widely used in COVID-19 diagnosis. However, clinicians may face
uncertainty in the disease diagnosis when one test is positive but the other is negative. We developed
a probabilistic model and a web application to synthesize the risks of having COVID-19 considering
three determining factors that included test sensitivity, specificity and pre-test probability. In serial
diagnostic tests applied on a same subject, inconsistent testing results might be observed as a result of
the change of underlying disease status rather than the power of the tests themselves. For example,
a patient that tested negative by PCR when first tested shortly after exposure, may not yet have
detectable virus, but could later test positive once viral loads are sufficient incubated. In application,
clinicians would also need to consider factors such as exposure risk before and between tests to
interpret results. Although the test results from the same subject are highly correlated, they are
conditionally independent, and thus the correlation will not affect the calculation of the posterior
probability. The second advantage for the Bayesian model is that suitable weights will be added to
the corresponding diagnostic tests according to their sensitivities and specificities, especially when the
weight for each test is hard to artificially determine. Multiple tests combined with our diagnostic tool
demonstrated improved diagnostic accuracy compared with individual tests.

To contain the outbreak of COVID-19, rapid and accurate diagnostic tests are critical. RT-PCR detects
the presence of the specific genetic material with generally high specificity but limited sensitivity. The
cHEST CT method, a valuable tool for the triage of suspected cases, is sensitive but prone to high false-
positive. A recent study reported that some patients were test-negative by RT-PCR, but radiological
evidence detected lung lesions compatible with COVID-19 [29]. The specificity of chest CT was

![Figure 3. Violin plot of the accuracy and precision for test #1, test #2 and the Bayesian probabilistic model. The pre-test probability is assumed from 0.001% to 25%, and sensitivities and specificities for both T1 and T2 are assumed from 55% to 100%.](https://royalsocietypublishing.org/doi/abs/10.1098/rsos.201867)
inconsistent in prior studies [30], which may be caused by the differences in study design of independent investigations and the differences in diagnostic experiences of thoracic radiologists. For antibody-based methods, the sensitivity and specificity are higher for combined IgM and IgG detection compared with using any of antibodies alone. However, antibodies were reported to appear after the onset of symptoms [26]. The presence of IgG is particularly delayed. Therefore, serological tests are more sensitive to detect infections after 7 days of symptom onset [31]. A negative serological test conducted in the early stage of disease onset may not be sufficient to rule out suspected cases. Comprehensive integration of multiple testing results, especially results from the rapid diagnostic tests with lower sensitivity and specificity, can provide a more accurate result.

During the surging phase of pandemic, the availability of RT-PCR is often affected by a shortage of laboratory test kits, long waiting time, complex operation, expensive equipment and lack of specialized technicians. Alternative testing methods might be applied to assist the diagnosis of COVID-19. Chest CT as a routine imaging method is often readily accessible in general hospitals. Serological tests, being fast and simple to perform, are also widely accepted in clinical and public health settings. High sensitivity is important for screening and diagnosing COVID-19, considering that asymptomatic cases also have a risk of spreading the virus, while specificity needs to be considered to avoid false treatment or nosocomial infection. Using the Bayesian probabilistic model could fully use the outcome of each detection method or testing sample and showed improved performance in COVID-19 diagnosis.

The main limitation of this study is that due to the lack of observational research data, the performance of the Bayesian method can only be evaluated through simulation models and pre-set cut-off values for positive diagnoses. However, the calculation of the posterior probability estimation will not be affected. The only impact caused by this inevitable limitation is that the absolute improvement for the performance of the Bayesian framework will be different in the real world.

The decision analytical model found that the probability of having COVID-19 calculated based on multiple testing varied with pre-test probabilities, which would be an important factor to consider, particularly in regions with increasing disease prevalence. Pre-test probability, an estimate of a person’s chance of being infected before testing, mainly depends on the local positive rate of COVID-19 among testing samples, SARS-CoV-2 exposure history and clinical signs [32]. Someone who is feeling unwell after close contact with suspected patients may have a higher risk of COVID-19 compared with local prevalence. The online tool developed in this study can assist physicians in performing a quick diagnosis onsite. The statistical underpinning of the proposed method is generic and can be applied to other infectious diseases.

5. Conclusion

Diagnostic tests for COVID-19 currently in use have varying sensitivity and specificity. As parallel and serial testing are widely used in the clinic to avoid missed diagnosis or misdiagnosis, we presented a Bayesian probabilistic framework that takes advantage of the outcome of multiple detection methods or testing samples for detecting COVID-19. We also developed a convenient online tool to display the posterior probability of being infected by SARS-CoV-2 by effectively integrating multiple COVID-19 tests. The online tool adds value to existing detection methods and can aid physicians in making clinical evaluations.

Ethics. Neither ethical approval nor individual consent is applicable.

Data accessibility. No real-world data are used in this study. The code is provided in the electronic supplementary material [33].

Authors’ contributions. M.H.W. conceived the study. L.C. conducted the literature review. S.Z. and M.H.W. carried out the analysis. L.C., S.Z., Q.L. and M.H.W. discussed the results. L.C. and S.Z. drafted the first manuscript. S.Z. and Q.L. developed the online tool. L.L., W.K.K.W., L.Z., J.L., M.K.C.C., Z.C., E.L.Y.W., B.C.Y.Z., M.T.V.C. and P.K.S.C. critically read and revised the manuscript and gave final approval for publication.

Competing interests. M.H.W. is a shareholder of Beth Bioinformatics Co., Ltd. B.C.Y.Z. is a shareholder of Beth Bioinformatics Co., Ltd and Health View Bioanalytics Ltd. Other authors declared no competing interests.

Funding. This work was supported by the National Natural Science Foundation of China (grant nos. 31871340, 71974165), Health and Medical Research Fund, the Food and Health Bureau, the Government of the Hong Kong Special Administrative Region (grant nos. COVID190103, INF-CUHK-1), and the Chinese University of Hong Kong (grant nos. PIEF/P1/COVID/06, 4054600).
1. WHO. 2020 Coronavirus Disease (COVID-19) Dashboard. See https://covid19.who.int/ (cited 2020).
2. Beeching NJ, Fletcher TE, Bedsworth MBJ. 2020 COVID-19: testing times. Br. Med. J. 369, m1403. (doi:10.1136/bmj.m1403)
3. Tang YW, Schmitz JE, Persing DH, Stratton CW. 2020 Laboratory diagnosis of COVID-19: current issues and challenges. J. Clin. Microbiol. 58, e00512-20. (doi:10.1128/jcm.00512-20)
4. Pasomsub E, Watcharananan SP, Boonyawat K, Janchompoo W, Wongtambit G, Sukswan W, Sugkanuparaph S, Phuphuakrat A. 2020 Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study. Clin. Microbiol. Infect. 27, 285.e1. (doi:10.1016/j.cmi.2020.05.001)
5. Wong HY et al. 2019 Frequency and distribution of chest radiographic findings in COVID-19 positive patients. Radiology 296, E72–E78. (doi:10.1148/radiol.2020201160)
6. He J, Luo L, Luo ZD, Lyu YJ, Nig MF, Shen XP, Wen Z. 2020 Diagnostic performance between CT and initial real-time RT-PCR for clinically suspected 2019 coronavirus disease (COVID-19) patients outside Wuhan, China. Respir. Med. 168, 105980. (doi:10.1016/j.rmed.2020.105980)
7. Mei K et al. 2020 Artificial intelligence-enabled rapid diagnosis of patients with COVID-19. Nat. Med. 26, 1224–1228. (doi:10.1038/s41591-020-0931-3)
8. Ai T, Yang Z, Hou H, Zhun C, Chen C, Lv W, Tao Q, Sun Z, Xia L. 2020 Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology 296, E22–E40. (doi:10.1148/radiol.2020200642)
9. Bai HH et al. 2020 Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology 296, E46–E54. (doi:10.1148/radiol.2020200823)
10. Li C, Ren L. 2020 Recent progress on the diagnosis of 2019 novel coronavirus. Transbound. Emerg. Dis. 67, 1485–1491. (doi:10.1111/tdb.13620)
11. Lou B et al. 2020 Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset. Eur. Respir. J. 56, 2000763. (doi:10.1183/13993003.00763-2020)
12. Delliave S, Salmona M, Minier M, Gabassi A, Alano A, Le Goff J, Delaugerre C, Chai A. 2020 Evaluation of COVID-19 IgG/IgM rapid test from origin gene biotech. J. Clin. Microbiol. 58, e01233-20. (doi:10.1128/jcm.01233-20)
13. Li Z et al. 2020 Development and clinical application of a rapid IgM/IgG combined antibody test for SARS-CoV-2 infection diagnosis. J. Med. Virol. 92, 1518–1524. (doi:10.1002/jmv.25727)
14. Cai XF et al. 2020 A peptide-based magnetic chemiluminescence enzyme immunoassay for serological diagnosis of coronavirus disease 2019 (COVID-19). J. Infect. Dis. 222, 189–193. (doi:10.1093/infdis/jiaa243)
15. Shen B et al. 2020 Clinical evaluation of a rapid colloidal gold immunochromatography assay for SARS-Cov-2 IgM/IgG. Am. J. Transl. Res. 12, 1348–1354.
16. Chee YF, Kim JW, Kwon HH, Hong HL, Jung CY, Jeon CH, Park EI, Kim SK. 2020 Diagnostic performance of immunochromatography assay for rapid detection of IgM and IgG in coronavirus disease 2019. J. Med. Virol. 92, 2567–2572. (doi:10.1002/jmv.26060)
17. Xu B, Xing Y, Peng J, Zheng Z, Tang W, Sun Y, Xu C, Peng F. 2020 Chest CT for detecting COVID-19: a systematic review and meta-analysis approach to modeling the conditional dependence between multiple diagnostic tests. Biometrics 57, 158–167. (doi:10.1111/biom.13416)
18. Lesaffre E. 2006 Estimating disease prevalence from case-control studies. Epidemiology 17, 145–153. (doi:10.1097/01.ede.0000192242.68018.8d)
19. Umemukue Chikere CM, Wilson K, Graziaio S, Vale L, Allen AJ. 2019 Diagnostic test evaluation methodologies: a systematic review of methods employed to evaluate diagnostic tests in the absence of gold standard diagnostic tests. BioMed Res. Int. 2019, 1374748. (doi:10.1155/2019/1374748)
20. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. 2020 Chest CT for typical coronavirus disease 2019 (COVID-19) pneumonia: relationship to negative RT-PCR testing. Radiology 296, E41–E45. (doi:10.1148/radiol.2020200341)
21. Adams HA, Kwok TC, Yaker D, Hope MD, Kwok RM. 2020 Systematic review and meta-analysis on the value of chest CT in the diagnosis of coronavirus disease (COVID-19). Sol Scientiae, Illustra Nos. 215, 1342–1350. (doi:10.2214/ajr.20.23391)
22. Erkens V, Spenbroek N, Prant et al. 2006 Estimating disease prevalence in a Bayesian framework using probabilistic constraints. Epidemiology 17, 145–153. (doi:10.1097/01.ede.0000192242.68018.8d)
23. Berkvens D, Speybroeck N, Praet N, Adel A, Mélinon B, Van Der Schueren B, Lesaffre E. 2006 Estimating disease prevalence from case-control studies. Epidemiology 17, 145–153. (doi:10.1097/01.ede.0000192242.68018.8d)
24. Boum Y et al. 2020 Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study. Lancet Infect. Dis. 21, 1089–1096. (doi:10.1016/s1473-3099(21)00132-8)
25. R Core Team. 2013 R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
26. Younes N, Al-Sadeq DW, Al-Jilhetteh H, Younes S, Al-Jamal O, Daas HH, Yassine HM, Nasrallah GK. 2020 Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2. Viruses 12, 582. (doi:10.3390/v12060582)
27. Lin C, Xiang J, Yan M, Li H, Huang S, Shen C. 2020 Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19). Chin. Chem. Lab. Med. 58, 1089–1094. (doi:10.1515/cclm-2020-0167)
28. Wu J, Liu J, Li S, Peng Z, Xiao Z, Wang X, Yan R, Luo J. 2020 Detection and analysis of nucleic acid in various biological samples of COVID-19 patients. Travel Med. Infect. Dis. 37, 101673. (doi:10.1016/j.tmaid.2020.101673)
29. Boum Y et al. 2020 Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study. Lancet Infect. Dis. 21, 1089–1096. (doi:10.1016/s1473-3099(21)00132-8)
30. Adams HA, Kwok TC, Yaker D, Hope MD, Kwok RM. 2020 Systematic review and meta-analysis on the value of chest CT in the diagnosis of coronavirus disease (COVID-19). Sol Scientiae, Illustra Nos. 215, 1342–1350. (doi:10.2214/ajr.20.23391)
31. Van Honacker E et al. 2020 Sensitivity and specificity of 14 SARS-CoV-2 serological assays and their diagnostic potential in RT-PCR negative COVID-19 infections. Acta Clin. Belg. 1–6. (doi:10.1080/17843266.2020.1861885)
32. Woloshin S, Patel N, Kesselheim AS. 2020 False negative tests for SARS-CoV-2 infection – challenges and implications. N. Engl. J. Med. 383, e38. (doi:10.1056/NEJMc2015897)
33. Cao M, Li et al. 2021 A Bayesian method for synthesizing multiple diagnostic outcomes of COVID-19 tests. F1000Research.